Dependence on Myb expression is attenuated in myeloid leukaemia with N-terminal CEBPA mutations by Volpe, Giacomo et al.
 
 
Dependence on Myb expression is attenuated in
myeloid leukaemia with N-terminal CEBPA
mutations
Volpe, Giacomo; Cauchy, Pierre; Walton, David S; Ward, Carl; Blakemore, Daniel; Bayley,
Rachael; Clarke, Mary L; Schmidt, Luisa; Nerlov, Claus; Garcia, Paloma; Dumon, Stéphanie;
Grebien, Florian; Frampton, Jon
DOI:
10.26508/lsa.201800207
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Volpe, G, Cauchy, P, Walton, DS, Ward, C, Blakemore, D, Bayley, R, Clarke, ML, Schmidt, L, Nerlov, C, Garcia,
P, Dumon, S, Grebien, F & Frampton, J 2019, 'Dependence on Myb expression is attenuated in myeloid
leukaemia with N-terminal CEBPA mutations' Life Science Alliance, vol. 2, no. 2, e201800207.
https://doi.org/10.26508/lsa.201800207
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 29. May. 2019
Research Article
Dependence on Myb expression is attenuated in myeloid
leukaemia with N-terminal CEBPA mutations
Giacomo Volpe1,2 , Pierre Cauchy3, David S Walton1, Carl Ward1,2 , Daniel Blakemore1, Rachael Bayley1, Mary L Clarke1,
Luisa Schmidt4 , Claus Nerlov5, Paloma Garcia1 , Ste´phanie Dumon1, Florian Grebien4,6 , Jon Frampton1
Mutations at the N- or C-terminus of C/EBPα are frequent in acute
myeloid leukaemia (AML) with normal karyotype. Here, we in-
vestigate the role of the transcription factor Myb in AMLs driven by
different combinations of CEBPA mutations. Using knockdown of
Myb inmurine cell linesmodelling the spectrumof CEBPAmutations,
we show that the effect of reduced Myb depends on the mutational
status of the two Cebpa alleles. Importantly, Myb knockdown fails to
override the block in myeloid differentiation in cells with biallelic
N-terminal C/EBPα mutations, demonstrating for the ﬁrst time that
the dependency on Myb is much lower in AML with this mutational
proﬁle. By comparing gene expression following Myb knockdown
and chromatin immunoprecipitation sequencing data for the
binding of C/EBPα isoforms, we provide evidence for a functional
cooperation between C/EBPα and Myb in the maintenance of AML.
This co-dependency breaks down when both alleles of CEBPA
harbour N-terminal mutations, as a subset of C/EBPα-regulated
genes only bind the short p30 C/EBPα isoform and, unlike other
C/EBPα-regulated genes, do so without a requirement for Myb.
DOI 10.26508/lsa.201800207 | Received 7 October 2018 | Revised 7 March
2019 | Accepted 7 March 2019 | Published online 15 March 2019
Introduction
Acute myeloid leukaemia (AML), one of the most common and
deadliest forms of proliferative neoplasms, is established through a
stepwise acquisition of genetic and epigenetic alterations that
result in the malignant transformation of haematopoietic pro-
genitor cells (Kelly & Gilliland, 2002; Moore, 2005). Often, AML arises
through the collaboration between mutations affecting transcrip-
tion factors (e.g., CEBPA, PU.1, and RUNX1) and signalling proteins
(such as FLT3, RAS, and KIT) that lead to an aberrant proliferation
capacity coupled with a disruption of terminal myeloid differen-
tiation (Tenen, 2003; Rosenbauer & Tenen, 2007).
C/EBPα, a leucine zipper transcription factor with a known tu-
mour suppressor function, has been demonstrated to play an
important role in granulocytic development and in the mainte-
nance of haematopoietic stem cell homeostasis (Porse et al, 2001,
2005; Zhang et al, 2004; Koschmieder et al, 2009; Welner et al, 2013;
Ye et al, 2013). C/EBPα is translated as twomajor isoforms, namely a
full-length 42-kD form (p42) and a truncated 30-kD protein (p30)
that arises from a downstream translational initiation codon (Lin
et al, 1993). Mutations in the CEBPA gene are frequently associated
with leukaemia, being found in 8–14% of all de novo AML with
normal karyotype (Nerlov, 2004; Leroy et al, 2005; Song et al, 2015)
and typically involve both alleles. C/EBPα-mutant proteins are
classiﬁed into two major groups: (i) C-terminal insertions or de-
letions within the basic region leucine zipper DNA-binding domain;
and (ii) N-terminal mutations that lead to the complete ablation of
p42 while retaining normal p30 function (Pabst et al, 2001; Leroy
et al, 2005; Fasan et al, 2014). Most patients carrying CEBPA mu-
tations harbour one allele with an N-terminal mutation and one
with a C-terminal mutation, with homozygosity for N- or C-terminal
mutations being less common (Gombart et al, 2002; Pabst &
Mueller, 2007). Furthermore, several reports have demonstrated
that biallelic mutations of CEBPA are associated with a favourable
outcome, when not found in association with FLT3-activating
mutations (Renneville et al, 2009; Dufour et al, 2010).
Efforts aimed at understanding how mutations or oncoproteins
may cooperate in driving the leukaemogenesis have pointed to
cooperation between C/EBPα and other transcription factors, such
as RUNX1, MYB, and PU.1. We have previously demonstrated the
functional cooperation of Myb and C/EBPα in the regulation of the
Flt3 gene in both haematopoietic and leukaemia stem cells (Volpe
et al, 2013, 2015). Our studies indicated that Myb and C/EBPα act
cooperatively through their combined activity on promoter and
intronic elements in the Flt3 gene (Volpe et al, 2013). Furthermore,
we reported a strong linear correlation between expression of the
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two transcription factors and FLT3 RNA levels in human CN-AML,
adding to an increasing body of evidence that points to MYB being a
crucial component of leukaemia maintenance and oncogene ad-
diction (Hess et al, 2006; Zuber et al, 2011; Clarke et al, 2017).
Our ﬁndings on the cooperation of Myb and C/EBPα in Flt3 gene
regulation prompted us to investigate the global extent of this co-
operation in leukaemia and to determine how manipulation of Myb
expression might impact on the maintenance of C/EBPα-driven leu-
kaemia. To address this, we performed geneticmanipulation studies in
murine haematopoietic progenitor cell lines harbouring either wild-
type C/EBPα or themost frequently occurring combinations of biallelic
CEBPA mutations, that is Nter/Nter or Nter/Cter to determine the bi-
ological and molecular consequences of reduced Myb activity on the
leukaemia driven by those mutations. Here, we show that reducing
Myb activity can override the differentiation barrier, although the
dependency on Myb expression generally observed in leukaemia is
minimal in the presence of CEBPA biallelic N-terminal mutations.
Materials and Methods
Cell lines
Cells were cultured in RPMI medium supplemented with 10% fetal
bovine serum, 50U/ml penicillin, 50 μg/ml streptomycin, and 2 mM
L-glutamine. The culture of FMH9 cells (Volpe et al, 2013) were
supplemented with 50 ng/ml stem cell factor, 5 ng/ml GM-CSF,
5 ng/ml IL-3 (IL3), and 5 ng IL-6 (IL6), whereas KL cells (GV, JF, and FG,
unpublished) and LL cells (Grebien et al, 2015; Schmidt et al, 2019)
required 2 ng/ml IL3. Both KL and LL have been established by serial
replating of E14.5 foetal liver cells obtained from mice homozygous
for the Lp30 allele (Kirstetter et al, 2008) or carrying both Lp30 and
K313KK alleles (Bereshchenko et al, 2009). Brieﬂy, the KL and LL cell
lines were obtained by performing six rounds of replating in M3434
semisolid medium (Stem Cell Technologies Inc) followed by an
initial liquid culture for 4 wk in the presence of stem cell factor (50
ng/ml), IL3 (2 ng/ml), and IL6 (2 ng/ml). After this initial period, the
cells were transferred into the culture medium described above. All
cytokines were purchased from Peprotech EC.
Transfection experiments, cell viability, proliferation, apoptosis,
and differentiation assays
In total, 5 × 106 FMH9, KL, or LL cells were electroporated with
300 mM of Myb siRNA (s70212, Ambion; Life Technologies) or a
scrambled negative control siRNA (4390843 Silencer Select Negative
Control #1; Life Technologies) using an Amaxa 4D-nucleofector with
solution SF Cell Line (V4XC-2024; Lonza) and program EO-100 for
FMH9 cells or solution P3 Primary Cells (V4XP-3024; Lonza) and
program DS-120 for KL and LL cells.
After transfection, the cells were plated at a density of 106 cells/ml
and viable cells counted and passaged at a ratio of 1:2 every 24 h for 4
consecutive days. Cell cycle analysis was performed by labelling
transfected cells (48 h post-nucleofection) with 10 μM BrdU for 1 h.
Cells were co-stained with 7-AAD (A9400-1mg; Sigma-Aldrich) and
BrdU using the BrdU ﬂow kit (8811-6600; BD Bioscience) according to
themanufacturer’s instructions, as previously described (Bayley et al,
2018). Apoptosis analysis was performed using the Annexin V kit
(eBioscience) as previously described (Volpe et al, 2015). The per-
centage of apoptotic cells was obtained by performing live cells
gating. Proliferation analysis was performed using CellTrace car-
boxyﬂuorescein succinimidyl ester (CFSE) Cell Proliferation Kit
(C34554; Thermoﬁsher Scientiﬁc). Assessment of differentiation fol-
lowing Myb knockdown was achieved by ﬂow cytometry/
immunoﬂuorescence staining of the cells with anti-CD11b PE-Cy7
(25-0112-81; eBioscience) anti-Gr-1 APC (14-5921-82; eBioscience),
anti-CD135 PE (12-1351-81; eBioscience), and anti-CD117 PE-Cy5 (15-
1171-82; eBioscience). Acquisition and analysis of ﬂow cytometric data
were performed using Cyan ADP with either Summit 4.4 software
(Beckman Coulter) or FlowJo software (FlowJo, LLC).
Quantitative reverse transcriptase polymerase chain reaction
(RT-PCR) analysis
106 cells from each line were harvested 24 h post-transfection. RNA
was extracted using RNeasy Mini kit (QIAGEN), and ﬁrst-strand cDNA
synthesis was performed using standard protocols. Quantitative
PCR reactions were performed using predesigned Taqman gene
expression assays as previously described (Volpe et al, 2015).
Statistical analysis
Statistical signiﬁcance was determined by performing t test for
pairwise comparison, and the P-values are indicated where ap-
propriate. Analysis of MYB expression in human patient array data
presented in Fig 1A was performed using non-parametric
Kruskal–Wallis test. All statistical analyses were performed using
GraphPad Prism 7 (GraphPad Software Inc).
Bioinformatic analyses
Details of the methodologies used to analyse and compare RNA-
seq, microarray, and ChIP-seq data, including Gene Ontology (GO)
and Gene Set Enrichment Analysis (GSEA) comparisons, can be
found in the Supplementary Information.
RNA-sequencing
For RNA-Seq, libraries were prepared using the Illumina TruSeq
Stranded kit according to the manufacturer’s instructions. Se-
quencing was performed at the Institute of Medical Biochemistry,
University of Veterinary Medicine, Vienna, Austria, and in Genomics
Birmingham, University of Birmingham, Birmingham, UK, on Illu-
mina HiSeq 2500 and NextSeq 500 sequencers, respectively.
Data availability
RNA-Seq data generated in this study are available at the Gene
Expression Omnibus under series GSE119348.
Results
High MYB expression is associated with CEBPA mutations in AML
Previous studies have provided evidence for functional cooperation
between C/EBPα and MYB in activating the expression of key genes
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for both haematopoietic and leukaemia stem cell functions inmouse
and human (Volpe et al, 2013, 2015, 2017). Using publicly available AML
patient proﬁling arrays (Verhaak et al, 2009) and focussing on speciﬁc
molecular abnormalities found in cytogenetically normal AML (CN-
AML), we observed that MYB expression levels are highest in those
patients carrying biallelic CEBPA mutations (Fig 1A).
Given the lack of a suitable cellular system to investigate the
relationship between MYB and C/EBPα in human AML, we used
murine cell lines modelling the spectrum of CEBPA mutations.
Bereshchenko and coworkers demonstrated that mutations in the
C/EBPα protein efﬁciently drive leukaemia in vivo and that the
combination of N- and C-terminal mutations were the most highly
leukaemogenic, whereas biallelic C-terminal mutation resulted in
the longest latency (Kirstetter et al, 2008; Bereshchenko et al, 2009).
We generated cell lines by performing serial replating in semisolid
medium of E14.5 foetal liver cells carrying knock-in modiﬁcations
mimicking either the N-terminal LP30 (L allele) or the C-terminal
K313KK (K allele) CEBPAmutations (Grebien et al, 2015). LL cells were
used to represent AML harbouring biallelic N-terminal CEBPA
mutations, whereas cells carrying one K mutation and one L mu-
tation (KL cells) provided a model of leukaemia with both N- and
C-terminal CEBPAmutations. AML with wild-type C/EBPα expression
was modelled using a previously characterised myelomonocytic
leukaemia cell line, namely, FMH9 (Volpe et al, 2013), which was
established by ectopic expression of HoxA9 and Meis1 in bone
marrow haematopoietic progenitor cells. The phenotype of these
cells lines was investigated by determining the surface expression
of several myeloid markers (CD11b, Gr1, Kit, and Flt3) (Fig S1A).
Importantly, mRNA quantiﬁcation indicated that both FMH9 and LL
cells displayed similarMybmRNA levels, whereas KL cells exhibited
a higher level of Myb expression (Fig 1B), thus being in agreement
with the observations obtained from the patient array data.
Manipulation of Myb expression does not reverse the
differentiation block in cells carrying biallelic N-terminal CEBPA
mutations
To investigate the requirement for Myb in the maintenance of
CEBPA-driven leukaemia, we performed siRNA-mediated knock-
down of Myb. Cells were transfected with siRNAs targeting either
Myb or a scrambled negative control and were harvested after 24 h
to determine the efﬁciency of knockdown. This analysis revealed a
decrease in Myb transcripts by 60–80% in all cell lines (Fig 1C).
To determine the biological consequences of Myb knockdown
cells were cultured for up to 96 h and cell numbers determined
daily.Myb down-regulation induced growth retardation in the three
cell lines, regardless of the CEBPA mutational status; albeit those
cells showing a similar pattern, the growth defect observed in FMH9
cells was signiﬁcantly more pronounced in comparison with the
CEBPAmutant cells lines (Figs 1D and S1B). Flow cytometric analysis
of CSFE dye dilution revealed that Myb knockdown induced a
signiﬁcant proliferation defect in FMH9 cells, whereas both KL and
LL cells were unaffected (Figs 1E and S1C). The pattern of the
proliferation defect observed in FMH9 cells 72 h post Myb down-
regulation appeared to be bimodal, probably because of cells being
induced to differentiate or due to the transient effect of the siRNA-
mediated knockdown. By combined staining with 7-AAD and BRDU
48 h post-transfection, we observed that Myb knockdown led to a
signiﬁcant increase in the proportion of cells in the G0/G1 phase
with a concomitant decrease in both S and G2/M phases in FMH9,
whereas KL and LL cells showed no alteration in their capacity to
progress through the cell cycle (Figs 1F and S2A, and B). This analysis
also revealed an increase in the percentage of cells with less than
2n DNA content in CEBPA-mutant cell lines only, this being in-
dicative of cells undergoing apoptosis/necrosis (Fig S2C). To con-
ﬁrm this observation, we performed Annexin V staining. This
revealed a signiﬁcant increase in the extent of apoptotic/necrotic
cells in both KL and LL cells, whereas no increase was observed in
FMH9 cells (Figs 1G and S3A).
Because it is accepted that homozygous CEBPA mutations lead
to a block in myeloid lineage commitment, we investigated how
Myb knockdown affects the differentiation capacity of cells in the
presence of either wild-type or biallelic mutant C/EBPα. At 96 h,
both FMH9 and KL cells exhibited a clear induction of myeloid
differentiation as indicated by increased expression of Gr-1 and
CD11b (Fig 2). However, this phenomenon was not observed in LL
cells, which is intriguing because it suggests that leukaemia cells
carrying biallelic N-terminal CEBPA mutations have a reduced
dependency on Myb expression in respect to differentiation
control.
Molecular consequences of Myb manipulation in cell lines
carrying either wild-type or mutant CEBPA
Myb was previously reported to suppress myeloid commitment
and to promote self-renewal in haematopoietic progenitors and
Figure 1. Myb expression is required for the proliferation of CEBPA biallelic mutant cell lines.
(A) Scatter plot depicting the abundance of MYB transcript in subgroups of patients from the Verhaak et al (2009) dataset, characterised by the molecular abnormalities
indicated in the graph. Statistical signiﬁcance presented in this plot has been calculated using non-parametric the Kruskal–Wallis test. (B) Bar plot representing
Myb mRNA quantiﬁcation by quantitative RT-PCR in FMH9, KL, and LL cell lines, normalised against B2m house-keeping gene results. Statistical analysis was performed
using t test (**P < 0.01 and *P < 0.05). (C) Quantitative RT-PCR of Myb transcript abundance in FMH9, KL, and LL cells 24 h post-transfection with Myb siRNA. Expression
is normalised to B2m and standardised to the control samples. Error bars represent the SEM and numbers are plotted as mean ± SEM. Each plot is representative
of six independent experiments (***P < 0.001 and *P < 0.05). (D) Bar plot indicating the cell viability and relative proliferation of FMH9, KL, and LL cells after Myb siRNA
transfection relative to the corresponding negative control (***P < 0.001 and **P < 0.01, *P < 0.05). This plot represents an average of six independent experiments. (E) Flow
cytometric analysis of cellular proliferation by CFSE incorporation in FMH9, KL, and LL cells after Myb siRNA transfection relative to the corresponding negative
control. Continuous lines indicate cells transfected with the negative control siRNA, whereas dashed lines indicate siMyb-transfected cells. The statistical analysis
was performed using t test on the geometric means of ﬂuorescence intensity for each time point comparing siNEG versus siMyb-treated cells, as indicated by the
colour-matched bar on top of every peak (**P < 0.01 and *P < 0.05). Each histogram is representative of six independent experiments. (F) Flow cytometric analysis of the cell
cycle in FMH9, KL, and LL cells was performed by staining with 7-AAD at 48 h after Myb siRNA transfection and compared with the negative control. Percentages of
cells in G0/G1 are indicated in each histogram. Each plot is indicative of six independent experiments. (G) Representative bar plot showing apoptosis analysis performed
by Annexin V staining 72 h post Myb siRNA transfection in FMH9, KL, and LL cells (***P < 0.001 and **P < 0.01). Each bar plot represents an average of six independent
experiments.
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leukaemia cells (Lorenzo et al, 2011; Zhao et al, 2011). We wished to
explore how the interplay between Myb and wild-type or mutant
C/EBPα inﬂuences the transcriptome, so we performed RNA-seq
analysis following Myb knockdown in the context of wild-type or
mutant C/EBPα. In line with previous reports, inspection of the RNA-
seq datasets for FMH9, KL, and LL cells showed the expected
patterns for typical myeloid genes that are known to be Myb targets,
such as Gﬁ1, Itgam/CD11b, Gr-1/Ly6d, and Ccnd2 (Fig S4A and B).
Analysis of the RNA-seq data by global correlation clustering of
fragments per kilobase of transcript per million mapped reads
(FPKM) in steady-state conditions (i.e., after control siRNA treatment
only) revealed higher similarity between KL and LL cells, with FMH9
cells clustering on their own, in line with previous reports on
biallelic CEBPA mutants (Wouters et al, 2009; Taskesen et al, 2011)
(Fig 3A). Differential gene expression analysis comparing control
and siMyb-transfected FMH9, KL, and LL cells revealed 790, 1217, and
40 genes being down-regulated, whereas 1364, 1668, and 329 genes
were up-regulated (Fig S5A). This demonstrates that, whereas FMH9
and KL cells display a large number of genes responsive to Myb
knockdown, LL cells exhibited only minor transcriptomic responses.
Intersection of the gene expression changes showed generally a
greater overlap of up-regulated genes than down-regulated genes
(Fig 3B), whereas hierarchical clustering revealed a higher degree of
similarity between gene expression changes in FMH9 and KL cells
Figure 2. Suppression of Myb expression overrides myeloid differentiation block in FMH9, KL but not in LL cells.
Two-dimensional ﬂow cytometric dot plot representing the analysis of CD11b and Gr-1 myeloid surface markers expression in FMH9, KL, and LL transfected with
either Myb siRNA or the corresponding control. The percentage of double-positive cells is indicated in every plot. The box plots in the right panel shows an average of
six independent experiments. Statistical signiﬁcance was calculated using t test (***P < 0.001).
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over changes observed in LL cells (Fig 3C). These ﬁndings conﬁrm
our hypothesis that the LL-mutant leukaemia phenotype is less
dependent on Myb.
We next investigated whether Myb knockdown results in dif-
ferential regulation of relevant gene ontologies. We examined
negative regulation of G1 to S phase transition (Ashburner et al,
2000), leukaemia stem cell state (Gal et al, 2006), response to AML
treatment (Bogni et al, 2006), and terminal myeloid differentiation,
computing average log2 siMyb/control fold changes for each on-
tologies (Table S1). We found that FMH9 and KL cells, but not LL cells,
exhibited down-regulation of the leukaemia stem cell gene ex-
pression programme following Myb knockdown (Figs 3D and S5B).
Crucially, this analysis also showed that speciﬁcally for FMH9 and KL
cells, siMyb treatment resulted in up-regulation of genes that are
also up-regulated during the treatment of AML.
To conﬁrm the observations obtained from the RNA-seq, we
performed quantitative RT-PCR analysis of selected key genes.
Signiﬁcantly, Cebpa mRNA was down-regulated upon Myb knock-
down in both FMH9 and KL cells, but not in LL cells. This suggests
that the functional cross-regulation between Myb and C/EBPα
could be lost in the presence of biallelic N-terminal CEBPA mu-
tations. This analysis conﬁrmed speciﬁc regulation by Myb of
differentiation-related genes in FMH9 and KL cells but not in LL cells
(Gﬁ1 and Sbno2), changes in the expression of genes leading to a
negative impact on proliferation in FMH9 cells (Ccnd2 and Sema4d),
and down- and up-regulation of genes related to increased apo-
ptosis seen in KL and LL cells (Prune2 and Dusp1) (Figs 3E and S4B).
Moreover, inspection of known Myb target genes revealed a sig-
niﬁcant repression of Bcl2 (Taylor et al, 1996; Salomoni et al, 1997), a
known anti-apoptotic regulator, in KL cells; concomitantly, we
observed the up-regulation of a pro-apoptotic gene normally anti-
correlated withMyb in AML, namely, Bcl2l11 (Bim) (Jing et al, 2015), in
LL cells. This is in agreement with the strong induction of apoptosis
observed in these cells upon Myb knockdown (Fig S3A and B).
Overall, the transcriptome changes following Myb knockdown in
cell lines with different CEBPAmutational status are consistent with
the corresponding phenotypic changes and further demonstrate
that cells with the biallelic LL C/EBPα conﬁguration lack a major
dependence on Myb.
Coincident binding of C/EBPα p42 and Myb correlates with gene
repression by Myb, whereas genes positively controlled by Myb
tend to bind C/EBPα p30
To shed light on the possible interplay between the mutational
status of C/EBPα and the Myb-dependent regulation of C/EBPα
target genes, we set out to investigate the chromatin binding
properties and transcriptional effects of C/EBPα p30, C/EBPα p42,
and K313KK-mutant C/EBPα isoforms. The N-terminal–mutant L
allele (Kirstetter et al, 2008) leads to the expression of the p30
isoform only, whereas the C/EBPα K313KK–mutant allele gives rise
to a C-terminal mutant that disables the DNA-binding domain,
resulting in a block in differentiation (Bereshchenko et al, 2009).
Because the binding dynamics of C/EBPα in double-mutant cells
would be technically difﬁcult to characterise, we used previously
published chromatin immunoprecipitation sequencing (ChIP-Seq)
data from a single isoform transfection model (Grebien et al, 2015).
This study used HA-tagged Cebpa constructs transfected into the
FDCP1 cell line (Bernard et al, 1991) and an immortalised IL3-
dependent murine myeloid cell line that approximates to the
wild-type C/EBPα leukaemia line FMH9 that we used for the Myb
knockdown studies. This latter study concurrently provided gene
expression microarray analysis of mock- and C/EBPα-transfected
cells. As expected, there were signiﬁcant increases in Cebpa
transcript abundance following overexpression of C/EBPα p30, C/
EBPα p42, and C/EBPα K313KK as compared with mock transfection
(Fig S6A, compare with Fig S6B in FMH9, KL, and LL cells). Analysis of
ChIP-seq data revealed 17,452, 22,873, and 68,432 peaks for C/EBPα
p30-, C/EBPα p42-, and C/EBPα K313KK–transfected cells, re-
spectively, which were mostly located in intergenic and intronic
regions (Fig S6C and D). However, visual inspection of the C/EBPα
K313KK dataset revealed low signal in K313KK peaks, hinting that
those are not speciﬁc, consistent with the loss of binding due to the
K313KK mutation in the DNA-binding domain (Grebien et al, 2015;
Bereshchenko et al, 2009). We next characterised speciﬁc p30 and
p42 peaks by ranking tag counts aroundmerged summits by p30/p42
fold change and identiﬁed 3,585 p42-speciﬁc, 19,949 shared, and 4,421
p30-speciﬁc peaks (Fig 4A). Although we did not use the C/EBPα
K313KK dataset as a direct base for comparison because of the
deleterious effect of the K allele on DNA binding, and thus low signal
to noise ratio, its binding pattern was mostly located in shared sites.
Crucially, by retrieving tag counts for Myb ChIP-Seq datasets, we
observed that Myb binding largely parallels that of p42 binding, both
in FDCP1 and in anMLL-AF9/NrasG12Dmurine AML cell line (Roe et al,
2015), although there was an overlap with some regions that pre-
dominantly bind p30 (Fig 4A). GO analysis of the p42-speciﬁc peaks
revealed signalling pathways involved in haematopoietic homeo-
stasis and pro-apoptotic genes (Fig 4B). Conversely, p30-speciﬁc
peaks were enriched in pluripotency genes, consistent with the
leukaemia stem cell signature seen amongst the up-regulated genes
following Myb knockdown in LL cells (Figs 3D and 4B, and S5B).
To characterise the consequences of C/EBPα binding on gene
expression, we performed GSEA using microarray datasets from
FDCP1 cells expressing p30, p42, and K313KK, ranking by log2 fold
change against mock transfection. We selected gene sets corre-
sponding to the closest genes of the top 1,000 peaks for cognate
ChIP-Seq datasets (p30, p42, and K313KK) in accordance with the
constraints of GSEA. We observed signiﬁcant correlations between
Figure 3. Myb down-regulation causes concomitant differential regulation of leukaemia gene expression programmes in both FMH9 and KL but not LL cells.
(A) Spearman correlation clustering of steady-state, control scrambled negative siRNA-transfected FMH9, KL, and LL cells. (B) Venn diagram overlaps of differentially
expressed genes in FMH9, KL, and LL cell lines following Myb knockdown. Left and right: signiﬁcantly down- and up-regulated genes, respectively. (C) Hierarchical
clustering of log2 fold changes resulting from siMyb treatment in FMH9, KL, and LL cells. (D) Average siMyb/siNEG log2 fold changes for leukaemia-relevant GO
classes. (E) RT-qPCR gene expression analysis of differentiation, apoptosis, and cell cycle genes post control and siMyb transfection. Relative expression values are
presented as ± SEM. Statistical analysis was performed using t test (***P < 0.001, **P < 0.01, and *P < 0.05). Each bar plot represents an average of six independent
experiments.
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p42-induced gene activation and p42 binding, as well as between
p30-induced gene repression and p30 binding (Fig 4C). However,
C/EBPα K313KK binding was not correlated with changes in gene
expression.
We next asked how C/EBPα isoform binding correlates with
genes whose expression is altered by Myb knockdown. We plotted
gene expression fold changes caused by Myb knockdown in FMH9,
KL, and LL cells against the ChIP-seq data ranking of p30/p42
binding. Two broad conclusions arise from this analysis: ﬁrst,
Myb-repressed genes largely bound p42 in the presence or absence
of p30; second, genes that are positively regulated by Myb are more
predominant amongst the group of genes that preferentially bind
p30 (Fig 4D and E). Conversely, p30 binding was linked with down-
regulation of gene expression upon Myb knockdown.
We next investigated the sequence content of p30- and p42-
speciﬁc sites by performing motif discovery analysis in the se-
quences corresponding to these peaks. This revealed that C/EBP,
AP-1, Ets, Myb, and Runx motifs were highly enriched in p42-speciﬁc
peaks (Fig S7A). However, the C/EBP motif was not enriched in the
p30-speciﬁc peaks. Instead, these peaks were enriched in CTCF, Nrf,
and Ets motifs. To conﬁrm these trends, we plotted motif matches
amongst increasing p30/p42 fold change as above. Strikingly, C/EBP
motifs seemed to be restricted to p42-speciﬁc and shared sites (Fig
S7B). Myb, Runx, AP-1, and Ets motifs also followed this trend.
Conversely, CTCF motifs were highly enriched in p30-speciﬁc sites
and to some extent in shared sites corresponding to lower p42
binding. Nrf, Sp1, and CREB motifs also seemed to follow this trend,
but not Elf motifs. To verify binding of cognate factors to these
motifs as well as active and inactive transcriptional hallmarks, we
made use of publicly available AML ChIP-Seq datasets (Yue et al,
2014; Roe et al, 2015). Our analysis revealed that C/EBPβ, an es-
sential transcription factor in normal myeloid development (Goode
et al, 2016), which is able to bind C/EBP motifs as well, also co-
localised with p42 (Fig S7C). Furthermore, by retrieving tag counts
for the transcription activation hallmark p300, we could also show
that p42-speciﬁc and shared sites, but not p30-speciﬁc sites,
correspond to putative enhancer sites, consistent with our GSEA
analyses for this isoform (Figs 4C and S7D).
Discussion
In the present study, we have investigated the requirement for the
transcription factor Myb in the maintenance of CN-AML driven by
different combinations of CEBPA mutations in comparison with
leukaemia characterised by the expression of wild-type C/EBPα. We
show for the ﬁrst time that the dependency on Myb is affected by
the mutational status of C/EBPα. Compared with cells expressing
wild-type C/EBPα, which show a proliferation and differentiation
response to enforced reduction in Myb levels, leukaemia driven by
biallelic CEBPA mutations exhibits distinct phenotypic responses
that are reﬂected in changes in gene expression. Furthermore,
leukaemia with biallelic Nter/Nter CEBPAmutations shows a reduced
dependency on Myb, whereas Cter/Nter mutant–driven AML cells are
as reliant on Myb as those expressing wild-type C/EBPα but exhibit
a quite distinct pattern of phenotype and gene expression changes
upon Myb knockdown.
Here, we show that knockdown of Myb in leukaemia cells har-
bouring either wild-type or Cter/Nter–mutant C/EBPα reverses the
abnormal myeloid phenotype normally observed in leukaemia,
whereas AML cells carrying biallelic Nter/Nter mutations exhibit
persistence of the undifferentiated phenotype. These behaviours
are reﬂected in distinct changes in gene expression. Hence, Myb
knockdown in leukaemia cells with wild-type or Cter/Nter–mutant
C/EBPα resulted in the loss of a leukaemia stem cell signature and
the up-regulation of a gene expression pattern generally observed
in patients that are responding to therapeutic treatment. In line
with previous reports (Zhao et al, 2014), our analysis demonstrated
Gﬁ1 and Sbno2, both of which encode transcription factors that can
be related to the loss of differentiation block, to be positive and
negative targets of Myb activity, respectively. The reduced de-
pendency of Nter/Nter–mutant C/EBPα–driven AML cells on Myb is
also paralleled by very little change in the number of genes affected
by Myb knockdown, including no effect on Gﬁ1 or Sbno2. In-
terestingly, Myb targets the expression of the Cebpa gene itself in
the wild-type and Cter/Nter C/EBPα contexts, suggesting positive
feedback that is not seen in C/EBPα Nter/Nter cells. This result
might provide a hint why LL leukaemia displays a different re-
sponse to Myb manipulation. Analysis of cell cycle and apoptosis
also revealed how knockdown of Myb can lead to quite a distinct
phenotype; for instance, although no induction in apoptosis/
necrosis was observed in C/EBPα wild-type cells, both mutant
cell lines displayed a large increase in the percentage of Annexin V+
cells and the appearance of a sub2n population, which is indicative
of cells undergoing cell death. However, it is possible that other
biological pathways could be affected that lead to such a different
response, with the cells perhaps being forced to engage in non-
apoptotic fates, such as necroptosis, autophagic cell death, or
pyroptosis (Tait et al, 2014); these possibilities remain to be further
elucidated.
Considering the different involvement of p30 and p42 in the
three leukaemia scenarios we have investigated, the fact that there
are p42-only– and p30-only–bound genes indicates that a distinct
response should be expected when Myb is reduced, especially
when only p30 is present. Most p42- or p42+p30–binding genes also
bind Myb, but interestingly, a signiﬁcant number of p30-only target
genes probably do not bind Myb. The genes that bound pre-
dominantly p42 fall into GO groups, including those associated with
Figure 4. p42 C/EBPα binding is linked with gene activation increased following Myb knockdown, whereas p30 C/EBPα binding correlates with gene repression
independently of Myb.
(A) Heat maps sorted by C/EBPα p30/p42 tag count fold change of ChIP-seq signals for C/EBPα p42, C/EBPα p42 K313KK, and C/EBPα p30 isoforms in the FDCP1
cell line, as well as for Myb and C/EBPα p42 in the RN2 cell line. (B) GO analyses of p42 and p30 C/EBPα-speciﬁc peaks (left, right). (C) Gene set enrichment analyses
of C/EBPα p30, C/EBPα p42, and C/EBPα p42-K313KK binding versus cognate-induced fold change (top left, top right, and bottom left, respectively). (A, D) Heat map
showing siMyb/siNEG gene expression fold change in FMH9, KL, and LL cells sorted by C/EBPα p30/p42 ChIP-seq tag count fold change as in (A). (A, D, E) Box plots
showing quantiﬁcation of gene expression fold changes from (D) for the nearest genes from groups 1, 2, and 3 deﬁned in (A). Means indicated.
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myeloid homeostasis and differentiation, consistent with the
ﬁnding that Myb knockdown restores myeloid differentiation.
Conversely, but in agreement with a persisting leukaemia pheno-
type not being affected by Myb manipulation, genes bound by p30
include pluripotency genes. This is in line with a previous report
that mature cells can tap into stem cell regulatory networks when
experiencing mutational hits in key differentiation factors (Soucie
et al, 2016).
The vast majority of genes affected by Myb knockdown in the
context of Nter/Nter biallelic–mutant C/EBPα are de-repressed and
overlap with genes similarly affected in the context of Cter/Nter. That
genes such as Dusp1 are not responsive to Myb changes in the
context of wild-type C/EBPα presumably means that p42, being fully
competent to dimerise and bind DNA is less dependent on Myb.
Mapping these gene expression changes onto the proﬁle of p42/
p30 binding revealed that they can be expected normally to bind
both p42 and p30. The large number of genes affected by Myb
knockdown that distinguished the response of Cter/Nter from Nter/
Nter are both down-regulated (1,188 genes) and up-regulated (1,423
genes), the majority of the former corresponding to genes that are
preferentially bound by p30. In contrast, the up-regulated genes,
normally repressed byMyb as seen in the Nter/Nter situation, tend to
be genes that exhibit greater binding by p42 when it is present.
Intriguingly, in the Nter/Nter situation, in which most of the genes
affected by Myb knockdown reﬂect loss of Myb-dependent re-
pression, these genes also fall into the category of preferential
binding to p42. Because no p42 is present in the Nter/Nter leukaemia,
this must mean that such genes can be regulated by Myb without a
prerequisite for cooperation with C/EBPα p42 or alternatively that
another C/EBP family protein such as C/EBPβ can act in place of
C/EBPα. In this circumstance, the proﬁle of C/EBPβ binding to genes
in the context of myeloid leukaemia cells parallels that of C/EBPα
p42. The consequence of this is that most of the genes bound by
C/EBPα p42 that are Myb dependent would not exhibit such re-
dundancy of C/EBP protein requirement.
By analysing the occurrence of transcription factor consensus
binding motifs in the sequence content of the C/EBPα ChIP-seq
peaks, we observed that the regulatory network maintaining the
different leukaemia statuses involves different possible sets of
transcription factor binding. p42-speciﬁc peaks are enriched in
C/EBP, Ap1, Myb, Ets, and Runx motifs, whereas the p30-speciﬁc
peaks contain mostly CTCF, Nrf, and Ets motifs. Importantly, we also
observed that p42-speciﬁc peaks that are also bound by Myb are
highly enriched in the transcription activation hallmark p300. This is
to be expected as p300 has been demonstrated to be one of the
most important cofactors for Myb and the inhibition of the Myb/
p300 interaction is crucial for the maintenance of the leukaemia
state (Pattabiraman et al, 2014). The same analysis performed for
the p30-speciﬁc peaks revealed those sites may be enriched for
CTCF in cells that do not express CEBPα p42 (Fig S7D).
In conclusion, we have shown that the nature of mutations in
one transcription factor that drives leukaemia can dictate how
another leukaemia-associated oncoprotein affects the mainte-
nance of the leukaemia phenotype. The precise nature of the in-
teractions between C/EBPα or its mutated variants and the Myb
protein on speciﬁc genes that dictate the leukaemia phenotype
remain to be elucidated, and it would be fruitful to assess in more
detail the relevance of this interaction in human leukaemia pa-
tients harbouring those mutations. Added complexity in the in-
volvement of C/EBP proteins in determining theMyb dependency of
a given leukaemiamost likely goes beyond solely the balance of the
C/EBPα isoforms, especially given the possibility that co-expressed
factors such as C/EBPβ might compete for binding to C/EBP motifs
and heterodimerise with C/EBPα. Ultimately, our ﬁndings call for a
larger study to determine how manipulating MYB would impact on
the maintenance of both murine and human leukaemia driven by
other genetic lesions.
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